#Phase 2

19 stories

Phase 2 is where peptide programs prove dose, target engagement, and proof-of-concept efficacy before committing to Phase 3 capital. Coverage on this site has tracked Phase 2 readouts and trial initiations across metabolic, oncology, and pulmonary indications.

Recent Phase 2 activity covered here: Boehringer Ingelheim's first-in-class triple GLP-1/GIP/NPY2 agonist BI 3034701 advancing to Phase 2 in mid-2026; Rein Therapeutics' LTI-03 Phase 2 RENEW trial with 8 patients enrolled in idiopathic pulmonary fibrosis; Bicycle Therapeutics dosing the first patient in a Phase 2 nuzefatide pevedotin trial in recurrent pancreatic cancer (April 2026); and Biomea Fusion's icovamenib COVALENT-112 52-week Phase 2 type-1 diabetes data showing a 52% C-peptide AUC increase. Several Roche, Pfizer, and AstraZeneca obesity-pipeline assets sit in Phase 2 readouts due before year-end 2026.

Stories here cover Phase 2 readouts, dose-selection decisions, and the bridge to Phase 3. See #phase-3, #clinical-trials, and #dose-selection.

Clinical Trials April 28, 2026 · View digest

Boehringer Advances BI 3034701: Gubra-Originated First-in-Class Triple GLP-1/GIP/NPY2 Agonist Heading to Phase 2 in Mid-2026

Boehringer Ingelheim disclosed alongside the survodutide topline that BI 3034701, a first-in-class triple GLP-1/GIP/NPY2 receptor agonist peptide, will enter Phase 2 in mid-2026. The compound completed a randomized placebo-controlled Phase 1 study in healthy volunteers and people with overweight/obesity that demonstrated favorable safety and tolerability and encouraging weight loss. BI 3034701 was developed in collaboration with Gubra, with Boehringer responsible for further development and global commercialization. The novel NPY2 component targets satiety pathways complementary to incretin agonism — a meaningful mechanistic differentiation in the next-gen obesity pipeline.